Expand CRVO Menu
CRVO MENU

CRVO Latest Press Releases

-- August 10, 2026 --

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- August 5, 2026 --

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 7:30 AM

-- August 4, 2026 --

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) Globe Newswire 5:15 AM

-- July 14, 2026 --

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) Globe Newswire 7:30 AM

-- July 9, 2026 --

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia Globe Newswire 7:30 AM

-- July 6, 2026 --

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 Globe Newswire 7:30 AM

-- June 22, 2026 --

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules Globe Newswire 4:05 PM

-- June 18, 2026 --

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules Globe Newswire 12:35 PM
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 Globe Newswire 7:00 AM

-- June 16, 2026 --

Wall Street Chases the Next Big Breakout Globe Newswire 3:22 PM
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum Globe Newswire 10:18 AM

-- June 12, 2026 --

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit Globe Newswire 7:30 AM

-- June 10, 2026 --

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- May 18, 2026 --

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- April 22, 2026 --

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- April 7, 2026 --

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting Globe Newswire 7:30 AM

-- March 19, 2026 --

CervoMed Announces New Data at the AD/PD 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology Globe Newswire 7:30 AM

-- March 17, 2026 --

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes